Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
other biotech firms
|
| gptkbp:can_lead_to |
gptkb:NTLA-2001
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:collaborations |
academic institutions
|
| gptkbp:employees |
over 200
|
| gptkbp:focus |
gene editing
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:founder |
gptkb:Jennifer_Doudna
|
| gptkbp:headquarters |
gptkb:San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
NTLA
|
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:research_areas |
genetic diseases
|
| gptkbp:stock_symbol |
gptkb:NTLA
|
| gptkbp:technology |
gptkb:CRISPR
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.ntl.com
|
| gptkbp:bfsParent |
gptkb:Intellia_Therapeutics
|
| gptkbp:bfsLayer |
4
|